Navigation Links
Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
Date:3/31/2008

MONMOUTH JUNCTION, N.J., March 31 /PRNewswire/ -- Transave, Inc., a biopharmaceutical company focused on developing innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases today announced that it has raised an aggregate of $35 million pursuant to its recently completed preferred stock offering. Joining the Company's Board are Richard Kollender from Quaker BioVentures and Steve Kraus from Bessemer Venture Partners, the lead investors in the Series D financing. Also participating in the financing were TVM Capital, Prospect Venture Partners, Fidelity Biosciences, Forbion Capital Partners and Easton Capital, all having previously taken a leading investment role in Transave.

"Proceeds from the financing will enable Transave to deliver Phase II proof of concept data for our lead clinical compound, ARIKACE(TM) (liposomal amikacin for inhalation). We are on track to have Arikace Phase II clinical data in cystic fibrosis patients that have Pseudomonas lung infections this year. In addition, Phase II bronchiectasis data will be available in the first half of 2009," said Tim Whitten, President and Chief Executive Officer of Transave.

Tim Whitten further commented, "We extend a hearty welcome to our newest Board Members, Rich Kollender and Steve Kraus who will add further depth to our Board. It is gratifying to receive significant financial support, not only from our highly-regarded new investors, but also from our existing investors. The new funding serves to validate the great strides Transave is making in our clinical programs based on our once-daily, next-generation liposomal pulmonary delivery technology. And perhaps more importantly, this financing will allow us to continue our mission to help patients that have serious chronic pulmonary infections."

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United
'/>"/>

SOURCE Transave, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
2. Moodys Raises Rating for Gerresheimer
3. SleepQuest Raises Awareness of Sleep Disorders
4. Arthrosurface Raises $4 Million of Preferred Equity Financing
5. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
6. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
7. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
8. Primera Biosystems Raises $21 Million in Series B Private Round
9. Cellectar, Inc. Raises $13 Million in Private Offering
10. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
11. Anesiva Raises $45 Million in Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website that ... used solely in scientific experiments, is currently celebrating its ... business, Maxim Peptide, which was created by the founders ... and updated website that now features a special deals ... updated with fascinating articles about peptide research, including a ...
(Date:7/11/2014)... 11, 2014 EPFL and the University of  ... appointment of John P. Donoghue . The American ... Geneva . The new Wyss Center ... Geneva , has named as its ... John P. Donoghue , founder of Brown University,s Institute ...
(Date:7/10/2014)... 2014 Women in the West ... an additional family planning option. Sayana® Press has ... all levels of the health system and in ... widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the ... the first of four African countries expected to ...
(Date:7/10/2014)... Terascala, the industry leader in HPC management ... vice president of product management for Flexera Software, has ... Terascala’s software when combined with leading compute and storage ... and most reliable solutions for processing big data. , ... and broaden its product portfolio. His leadership in startups ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... ALS Lab Presents on Therapy Development StrategyCAMBRIDGE, Mass., ... (ALS TDI) has announced the 2009 launch of ... two-hour, interactive seminar is designed to inform and ... worldwide efforts to discover and develop effective treatments ...
... -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" ... operations in the,People,s Republic of China, today announced its ... 2009 ended December 31, 2008. , , ... -- Revenue was $32.9 million, up 24.1% ...
... potential) of stem cells and accelerates development of ... announces today the introduction of its GT(TM) Flow ... Summit to be held in New York, NY. ... validated, scalable technology for customizing the biological activity ...
Cached Biology Technology:Seminar Will Bring ALS Researchers to Patient Groups 2Seminar Will Bring ALS Researchers to Patient Groups 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 2MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 3
(Date:7/13/2014)... French . ... project, led by the Research Institute of the McGill ... new oral medication is showing significant progress in restoring ... now, this inherited retinal disease that causes visual impairment ... untreatable. The study is published today in the scientific ...
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... Research awarded Michael F. Holick, PhD, MD, of Boston ... V. Avioli Award. Holick, a professor of medicine, physiology ... the understanding of vitamin D and its role in ... of the American Society for Bone and Mineral Research ... research. It is named for ASBMR,s first president and ...
Breaking Biology News(10 mins):MUHC researcher unveils novel treatment for a form of childhood blindness 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... for more than 50 years as one of the ... disorder. However, scientists have never been entirely sure ... from Cardiff University scientists suggests a possible mechanism for ... of the illness and potentially more effective treatments. ...
... obese people become salt sensitive and hypertensive has been ... They,ve documented a chain of events in which excess ... to retain more sodium and, consequently, more fluid and ... cardiologist at MCG,s Georgia Prevention Institute. Their findings ...
... carbon dioxide continues to burgeon in the atmosphere causing the ... to remove the excess gas from the atmosphere and store ... Gislason of the University of Iceland has been studying the ... basalt and presented his findings today to several thousand geochemists ...
Cached Biology News:Connection elucidated between obesity, salt sensitivity and high blood pressure 2Storing carbon dioxide deep underground in rock form 2
...
...
...
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
Biology Products: